{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:00:26Z","timestamp":1761872426443,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.08.002","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T20:30:43Z","timestamp":1691353843000},"page":"786-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation"],"prefix":"10.1016","volume":"23","author":[{"given":"Ilaria","family":"Romano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalgisa","family":"Condoluci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2023.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.08.002_bib0002","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.08.002_bib0003","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.08.002_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.829983","article-title":"Biology and treatment of Richter transformation","volume":"12","author":"Condoluci","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.08.002_bib0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"10.1016\/j.clml.2023.08.002_bib0006","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.08.002_bib0007","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.08.002_bib0009","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"10232","key":"10.1016\/j.clml.2023.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.clml.2023.08.002_bib0011","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2023.08.002_bib0012","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.08.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235816","article-title":"Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment","volume":"13","author":"Marvyin","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.clml.2023.08.002_bib0014","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ajcp\/aqz109","article-title":"Peripheral T-cell lymphoma arising in patients with chronic lymphocytic leukemia","volume":"152","author":"Van Der Nest","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.clml.2023.08.002_bib0015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\"accelerated\" chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2023.08.002_bib0016","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0017","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/1097-0142(19900701)66:1<140::AID-CNCR2820660125>3.0.CO;2-I","article-title":"Single clonal origin of neoplastic B-cells with different immunoglobulin light chains in a patient with Richter's syndrome","volume":"66","author":"Miyamura","year":"1990","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2023.08.002_bib0018","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.clml.2023.08.002_bib0019","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"issue":"15","key":"10.1016\/j.clml.2023.08.002_bib0020","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.08.002_bib0021","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2023.08.002_bib0022","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clml.2023.08.002_bib0024","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.08.002_bib0025","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","article-title":"Richter\u2019s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0026","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/asheducation-2018.1.256","article-title":"Richter transformation in the era of novel agents","volume":"2018","author":"Ding","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"15","key":"10.1016\/j.clml.2023.08.002_bib0027","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.08.002_bib0028","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2021.278304","article-title":"The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation","volume":"107","author":"Visentin","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.08.002_bib0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.08.002_bib0030","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2023.08.002_bib0031","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"issue":"18","key":"10.1016\/j.clml.2023.08.002_bib0032","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.08.002_bib0033","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value\u2009>\u200910 represents a novel valid marker for discerning Richter's syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2023.08.002_bib0034","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cpet.2019.03.007","article-title":"PET\/computed tomography in chronic lymphocytic leukemia and richter transformation","volume":"14","author":"Rhodes","year":"2019","journal-title":"PET Clin"},{"issue":"1-2","key":"10.1016\/j.clml.2023.08.002_bib0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10428199909145949","article-title":"Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study","volume":"36","author":"Giles","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2023.08.002_bib0036","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/10428190290016872","article-title":"Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders","volume":"43","author":"Tsimberidou","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2023.08.002_bib0037","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.08.002_bib0038","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2023.08.002_bib0039","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2023.08.002_bib0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0041","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.08.002_bib0042","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.08.002_bib0043","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2023.08.002_bib0044","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.08.002_bib0045","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.08.002_bib0046","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.08.002_bib0047","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1097\/HS9.0000000000000870","article-title":"Zanubrutinib, alone and in combination with tislelizumab, for the treatment of richter transformation of chronic lymphocytic leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.clml.2023.08.002_bib0048","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/jpm11080764","article-title":"Non-vovalent BTK inhibitors-the new BTKids on the block for B-cell malignancies","volume":"11","author":"Lewis","year":"2021","journal-title":"J Pers Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0049","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2022-157058","article-title":"Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1\/2 BRUIN study","volume":"140","author":"Wierda","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0050","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.08.002_bib0051","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.clml.2023.08.002_bib0052","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.08.002_bib0053","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.08.002_bib0054","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","article-title":"Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort","volume":"100","author":"Bouclet","year":"2021","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.08.002_bib0055","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.002_bib0056","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hon.3164_343","article-title":"Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter syndrome","volume":"41","author":"Davids","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2023.08.002_bib0057","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/01.HS9.0000845488.18043.aa","article-title":"Venetoclax-based treatment of patients with Richter syndrome: outcomes from a multicenter retrospective study","volume":"6","author":"Hampel","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0058","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bjh.15440","article-title":"BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome","volume":"185","author":"Visentin","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0059","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-138811","article-title":"Updated results from a phase I\/II study of duvelisib and venetoclax in patients with relapsed or refractory CLL\/SLL or Richter's syndrome","volume":"136","author":"Crombie","year":"2020","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2023.08.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.396.396","article-title":"The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed \/refractory non Hodgkin's lymphoma (NHL)","volume":"124","author":"Kuruvilla","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.08.002_bib0061","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-21-3867","article-title":"Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: a phase I study","volume":"28","author":"Stephens","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.clml.2023.08.002_bib0062","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.08.002_bib0063","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.08.002_bib0064","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0065","article-title":"A phase I trial of PI3K\u03b1\u03b4 Inhibitor copanlisib in combination with nivolumab in patients with Richter's transformation (RT) or transformed non-Hodgkin lymphoma (tNHL)","volume":"138","author":"Shouse","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.002_bib0066","series-title":"International Workshop on CLL, September 17-20, 2021, virtual (poster 1083523)","article-title":"Phase I\/II study of umbralisib, ublituximab, and pembrolizumab in patients with relapsed or refractory chronic lymphocytic leukemia and Richter's transformation: 5-year follow-up","author":"Roeker","year":"2021"},{"issue":"suppl 2","key":"10.1016\/j.clml.2023.08.002_bib0067","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.3163_27","article-title":"Efficacy and safety of molto, a multicenter, open label, phase ii clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome","volume":"41","author":"Frustaci","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0068","article-title":"Venetoclax, obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for treatment for patients with richter transformation","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.08.002_bib0069","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","article-title":"A phase two study of high dose blinatumomab in Richter's syndrome","volume":"36","author":"Thompson","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0070","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1182\/blood-2022-159695","article-title":"Blinatumomab for patients with Richter syndrome: final results of the phase 2 Blinart trial from the filo group","volume":"141","author":"Guieze","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.08.002_bib0071","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol."},{"issue":"suppl 2","key":"10.1016\/j.clml.2023.08.002_bib0072","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.3163_28","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter's transformation","volume":"41","author":"Carlo-Stella","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0073","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.002_bib0074","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hon.3166_OT10","article-title":"Epcoritamab monotherapy and combinations in relapsed or refractory chronic lymphocytic leukemia or Richter's syndrome: new escalation and expansion cohorts in EPCORE CLL-1","volume":"41","author":"Eichhorst","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-022-00279-w","article-title":"CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model","volume":"11","author":"Chauchet","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"S1","key":"10.1016\/j.clml.2023.08.002_bib0076","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/blood-2022-169171","article-title":"First-in-human (FIH) study of the fully-human kappa-lambda CD19\/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma","volume":"140","author":"Hawkes","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0077","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid"},{"issue":"24","key":"10.1016\/j.clml.2023.08.002_bib0078","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0079","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1182\/blood-2022-163509","article-title":"Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of zilovertamab vedotin (MK-2140) in non-Hodgkin lymphoma","volume":"140","author":"Spurgeon","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.08.002_bib0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clml.2023.08.002_bib0081","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.08.002_bib0082","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2020003726","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation","volume":"5","author":"Lahoud","year":"2021","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.clml.2023.08.002_bib0083","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2023.08.002_bib0084","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3324\/haematol.2021.279033","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.08.002_bib0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.08.002_bib0086","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41591-021-01248-2","article-title":"Author Correction: determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"27","author":"Fraietta","year":"2021","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.002_bib0087","article-title":"Safety and efficacy of CD19-CAR T cells in Richter's transformation after targeted therapy for chronic lymphocytic leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2023.08.002_bib0088","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.clml.2023.08.002_bib0089","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2023.08.002_bib0090","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.08.002_bib0091","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.clml.2023.08.002_bib0092","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.08.002_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.828471","article-title":"Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter's transformation","volume":"12","author":"Ortiz-Maldonado","year":"2022","journal-title":"Front Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:15Z","timestamp":1761871395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002355"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}